CN104220450B - 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5-胆甾烯-3β,25-二醇二硫酸酯(25HCDS) - Google Patents

用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5-胆甾烯-3β,25-二醇二硫酸酯(25HCDS) Download PDF

Info

Publication number
CN104220450B
CN104220450B CN201380019476.3A CN201380019476A CN104220450B CN 104220450 B CN104220450 B CN 104220450B CN 201380019476 A CN201380019476 A CN 201380019476A CN 104220450 B CN104220450 B CN 104220450B
Authority
CN
China
Prior art keywords
compound
25hcds
cholestene
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380019476.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN104220450A (zh
Inventor
S·任
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
Original Assignee
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University filed Critical Virginia Commonwealth University
Priority to CN201610412359.9A priority Critical patent/CN106083976B/zh
Publication of CN104220450A publication Critical patent/CN104220450A/zh
Application granted granted Critical
Publication of CN104220450B publication Critical patent/CN104220450B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380019476.3A 2012-04-12 2013-03-15 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5-胆甾烯-3β,25-二醇二硫酸酯(25HCDS) Expired - Fee Related CN104220450B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610412359.9A CN106083976B (zh) 2012-04-12 2013-03-15 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5‑胆甾烯‑3β,25‑二醇二硫酸酯(25HCDS)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261623203P 2012-04-12 2012-04-12
US201261623414P 2012-04-12 2012-04-12
US61/623,414 2012-04-12
US61/623,203 2012-04-12
PCT/US2013/031861 WO2013154752A1 (en) 2012-04-12 2013-03-15 A NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3β-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVER DISEASES AND ATHEROSCLEROSIS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610412359.9A Division CN106083976B (zh) 2012-04-12 2013-03-15 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5‑胆甾烯‑3β,25‑二醇二硫酸酯(25HCDS)

Publications (2)

Publication Number Publication Date
CN104220450A CN104220450A (zh) 2014-12-17
CN104220450B true CN104220450B (zh) 2016-07-06

Family

ID=49328028

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380019476.3A Expired - Fee Related CN104220450B (zh) 2012-04-12 2013-03-15 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5-胆甾烯-3β,25-二醇二硫酸酯(25HCDS)
CN201610412359.9A Expired - Fee Related CN106083976B (zh) 2012-04-12 2013-03-15 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5‑胆甾烯‑3β,25‑二醇二硫酸酯(25HCDS)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610412359.9A Expired - Fee Related CN106083976B (zh) 2012-04-12 2013-03-15 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5‑胆甾烯‑3β,25‑二醇二硫酸酯(25HCDS)

Country Status (20)

Country Link
US (6) US20150072962A1 (https=)
EP (2) EP2836502B1 (https=)
JP (4) JP6125610B2 (https=)
KR (1) KR102180485B1 (https=)
CN (2) CN104220450B (https=)
AU (2) AU2013246435B2 (https=)
BR (1) BR112014025081B1 (https=)
CA (1) CA2867694C (https=)
DK (1) DK2836502T3 (https=)
EA (1) EA026683B1 (https=)
ES (1) ES2641841T3 (https=)
HU (1) HUE035073T2 (https=)
IL (1) IL234892B (https=)
IN (1) IN2014KN02366A (https=)
MX (1) MX357046B (https=)
PL (1) PL2836502T3 (https=)
PT (1) PT2836502T (https=)
SI (1) SI2836502T1 (https=)
WO (1) WO2013154752A1 (https=)
ZA (1) ZA201406981B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106083976A (zh) * 2012-04-12 2016-11-09 弗吉尼亚联邦大学 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5‑胆甾烯‑3β,25‑二醇二硫酸酯(25HCDS)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
HRP20220112T1 (hr) * 2013-12-24 2022-04-15 Virginia Commonwealth University Upotreba oksidacijskog sulfata kolesterola (ocs) za liječenje akutne insuficijencije jetre
TWI547280B (zh) * 2014-04-24 2016-09-01 長弘生物科技股份有限公司 穩定醫藥組合物
US10238664B2 (en) 2014-07-09 2019-03-26 Duke University Compositions and methods for the repair of myelin
EP3204013A1 (en) * 2014-10-10 2017-08-16 Virginia Commonwealth University Oxygenated cholesterol sulfates for therapy of disorders caused by at least one of attenuated leptin activity and a lipid storage disorder
JP6784963B2 (ja) * 2014-12-24 2020-11-18 国立大学法人京都大学 ビタミンｄ３誘導体及びその薬学的用途
EP3493810A4 (en) 2016-08-02 2020-04-08 Durect Corporation COMPOSITIONS WITH OXYGENOUS CHOLESTERINSULFATE AND AT LEAST POLYALKYLENE GLYCOL, CARBOXYMETHYLCELLULOSE OR POLYOXYL GLYCERIDE
EP3494125B1 (en) * 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
KR20230124756A (ko) * 2016-08-02 2023-08-25 버지니아 커먼웰스 유니버시티 염증성 피부 질환 및 피부 병변을 치료하기 위한 산소첨가된콜레스테롤 술페이트 (ocs) 의 용도
EP4537847A3 (en) * 2017-01-13 2025-07-30 Duke University Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
KR101892577B1 (ko) 2017-04-21 2018-08-28 부산대학교 산학협력단 레블라스타틴 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 죽상동맥경화증 예방 또는 치료용 조성물
CN107286160A (zh) * 2017-06-05 2017-10-24 毛佳婧 一种抗肝炎药物的哌啶并吡啶并吡唑‑锌配合物的制备方法
US20200197471A1 (en) * 2017-08-31 2020-06-25 Ariel Scientific Innovations Ltd S. spinosum extract for treating fatty liver disease
JP7830313B2 (ja) * 2019-09-30 2026-03-16 デュレクト コーポレーション アルコール性肝炎の処置
JP2023532286A (ja) * 2020-06-26 2023-07-27 デュレクト コーポレーション 炎症状態を処置するための酸素化コレステロールスルフェート類の使用
CN112294827B (zh) * 2020-11-12 2021-12-24 四川大学华西医院 5-胆甾烯 -3β-醇硫酸酯盐的用途
KR102732697B1 (ko) 2021-10-29 2024-11-25 부산대학교 산학협력단 크산틴 유도체를 유효성분으로 포함하는 죽상동맥경화증 예방 또는 치료용 약학적 조성물
WO2024008614A1 (en) * 2022-07-08 2024-01-11 Société des Produits Nestlé S.A. Use of 25-hydroxycholesterol for diabetic treatment and/or prevention

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1357003A (zh) * 1999-04-30 2002-07-03 亚其发展公司 类固醇衍生物
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1983972A4 (en) 2006-02-13 2012-01-25 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
WO2009002873A1 (en) 2007-06-22 2008-12-31 Cvi Pharmaceuticals Limited Compounds, compositions and methods for reducing lipid levels
WO2011077245A2 (en) * 2009-12-23 2011-06-30 Fondazione Centro San Raffaele Del Monte Tabor Compositions
US20150072962A1 (en) * 2012-04-12 2015-03-12 Virgini Commonwealth University Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1357003A (zh) * 1999-04-30 2002-07-03 亚其发展公司 类固醇衍生物
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
24-Hydroxycholesterol Sulfation by Human Cytosolic Sulfotransferases: Formation of Monosulfates and Disulfates,Molecular Modeling, Sulfatase Sensitivity, and Inhibition of Liver X Receptor Activation;Ian T. Cook等;《DRUG METABOLISM AND DISPOSITION》;20091231;第37卷(第10期);第2069-2078页 *
25-Hydroxycholesterol-3-sulfate regulates macrophage lipid metabolism via the LXR/SREBP-1 signaling pathway;Yongjie Ma等;《Am.J.Physiol.Endocrinol.Metab.》;20081014;第295卷(第6期);第1369-1379页 *
Sulfated oxysterol, 25HC3S, is a potent regulator of lipid metabolism in human hepatocytes;Shunlin Ren等;《Biochemical and Biophysical Research Communications》;20070907;第360卷(第4期);第802-808页 *
孕甾-5-烯23β, 20-二取代硫酸酯钠盐的合成;李莹等;《广西师范学院学报（自然科学版）》;20090630;第26卷(第2期);第52-54页 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106083976A (zh) * 2012-04-12 2016-11-09 弗吉尼亚联邦大学 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5‑胆甾烯‑3β,25‑二醇二硫酸酯(25HCDS)
CN106083976B (zh) * 2012-04-12 2018-02-09 弗吉尼亚联邦大学 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5‑胆甾烯‑3β,25‑二醇二硫酸酯(25HCDS)

Also Published As

Publication number Publication date
CN104220450A (zh) 2014-12-17
EA026683B1 (ru) 2017-05-31
US20180127457A1 (en) 2018-05-10
HUE035073T2 (en) 2018-05-02
IL234892B (en) 2019-02-28
MX357046B (es) 2018-06-22
CN106083976B (zh) 2018-02-09
EP3239163A1 (en) 2017-11-01
MX2014012324A (es) 2015-05-11
EP2836502A1 (en) 2015-02-18
US20200157140A1 (en) 2020-05-21
EP2836502A4 (en) 2015-08-19
US20190135856A1 (en) 2019-05-09
CA2867694C (en) 2021-08-31
PL2836502T3 (pl) 2018-01-31
AU2017268646A1 (en) 2017-12-21
US20160355544A1 (en) 2016-12-08
ES2641841T3 (es) 2017-11-14
SI2836502T1 (sl) 2017-11-30
BR112014025081A2 (pt) 2018-05-08
AU2013246435B2 (en) 2017-10-05
AU2017268646B2 (en) 2019-07-11
JP2019089777A (ja) 2019-06-13
KR102180485B1 (ko) 2020-11-18
JP2015512937A (ja) 2015-04-30
JP6125610B2 (ja) 2017-05-10
PT2836502T (pt) 2017-10-27
JP2017160213A (ja) 2017-09-14
KR20150013520A (ko) 2015-02-05
DK2836502T3 (en) 2017-10-23
IN2014KN02366A (https=) 2015-05-01
AU2013246435A1 (en) 2014-10-16
EP2836502B1 (en) 2017-08-02
ZA201406981B (en) 2016-05-25
EA201491859A1 (ru) 2015-02-27
HK1202294A1 (en) 2015-09-25
WO2013154752A1 (en) 2013-10-17
CA2867694A1 (en) 2013-10-17
JP2021138713A (ja) 2021-09-16
BR112014025081B1 (pt) 2020-12-08
CN106083976A (zh) 2016-11-09
US20150072962A1 (en) 2015-03-12
US20210238219A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
CN104220450B (zh) 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5-胆甾烯-3β,25-二醇二硫酸酯(25HCDS)
US11384115B2 (en) Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
Lifsey et al. Stigmasterol stimulates transintestinal cholesterol excretion independent of liver X receptor activation in the small intestine
US8399441B2 (en) Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
BR112018068278B1 (pt) Derivado de 3-desóxi, ácido livre, sal e conjugado de aminoácido, composição farmaceutica compreendendo o referido composto e seu uso
Zheng et al. Anhydroicaritin improves diet-induced obesity and hyperlipidemia and alleviates insulin resistance by suppressing SREBPs activation
Jun et al. Iristectorigenin B isolated from Belamcanda chinensis is a liver X receptor modulator that increases ABCA1 and ABCG1 expression in macrophage RAW 264.7 cells
Kazakova et al. Hepatoprotective activity of Betulin and Dipterocarpol derivatives
HK1202294B (en) A novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty liver diseases and atherosclerosis
Zhou et al. Δ24-Dehydrocholesterol reductase (DHCR24): A novel target for the treatment of nash
Liu et al. 25-Hydroxycholesterol activates the expression of cholesterol 25-hydroxylase in an

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160706